Skip to main content
SpringerLink
Log in

Systemic Onco-Sphere: Host Metabolic System and Cancer

  • Chapter
  • First Online:
Tumor Ecosystem

  • 309 Accesses

Abstract

It is well established that patients with altered metabolism manifesting as obesity, metabolic syndrome and chronic inflammation have an increased incidence of cancer; indicating a crucial relationship between host metabolic system and cancer growth. However, the impact of the systemic metabolic system in the host on the local onco-sphere has not been deeply studied especially on how the host dysregulated metabolism could affect the drug absorption and excertion to have significant effect on tumor has not been studied in detail. Interestingly, more research is now supporting the idea that metabolic states and disorders linked to obesity affect not only the number of people who get cancer but also how well they respond to treatments like radiation and chemotherapy. Therefore, in this chapter, we discuss on the host metabolic diseases and how these changes therapeutic efficacy of cancer-related drugs, and the underlying mechanism which might be responsible to this phenomenon. This chapter details the importance of host metabolic changes in cancer progression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8(6):519–530

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A et al (2017) Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 377(1):13–27

    Article  PubMed  Google Scholar 

  3. Wright CM, Shastri AA, Bongiorno E, Palagani A, Rodeck U, Simone NL (2020) Is host metabolism the missing link to improving cancer outcomes? Cancer 12(9):2338

    Article  CAS  Google Scholar 

  4. Pothiwala P, Jain SK, Yaturu S (2009) Metabolic syndrome and cancer. Metab Syndr Relat Disord 7(4):279–288

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Russo A, Autelitano M, Bisanti L (2008) Metabolic syndrome and cancer risk. Eur J Cancer 44(2):293–297

    Article  PubMed  Google Scholar 

  6. Larsson SC, Wolk A (2007) Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 86(3):556–565

    Article  CAS  PubMed  Google Scholar 

  7. Larsson SC, Wolk A (2007) Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 97(7):1005–1008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Larsson SC, Wolk A (2007) Body mass index and risk of multiple myeloma: a meta-analysis. Int J Cancer 121(11):2512–2516

    Article  CAS  PubMed  Google Scholar 

  9. Larsson SC, Wolk A (2007) Obesity and the risk of gallbladder cancer: a meta-analysis. Br J Cancer 96(9):1457–1461

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Larsson SC, Orsini N, Wolk A (2007) Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer 120(9):1993–1998

    Article  CAS  PubMed  Google Scholar 

  11. Larsson SC, Wolk A (2008) Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. Int J Cancer 122(6):1418–1421

    Article  CAS  PubMed  Google Scholar 

  12. Olsen CM, Nagle CM, Whiteman DC, Purdie DM, Green AC, Webb PM (2008) Body size and risk of epithelial ovarian and related cancers: a population-based case-control study. Int J Cancer 123(2):450–456

    Article  CAS  PubMed  Google Scholar 

  13. Jensen A, Sharif H, Olsen JH, Kjaer SK (2008) Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am J Epidemiol 168(1):49–57

    Article  PubMed  Google Scholar 

  14. McCourt CK, Mutch DG, Gibb RK, Rader JS, Goodfellow PJ, Trinkaus K et al (2007) Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol 104(3):535–539

    Article  PubMed  Google Scholar 

  15. Patel AV, Feigelson HS, Talbot JT, McCullough ML, Rodriguez C, Patel RC et al (2008) The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer 123(8):1877–1882

    Article  CAS  Google Scholar 

  16. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335(7630):1134

    Article  PubMed  PubMed Central  Google Scholar 

  17. Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Yu MC (2002) Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes Control 13(3):287–293

    Article  PubMed  Google Scholar 

  18. Flood A, Mai V, Pfeiffer R, Kahle L, Remaley AT, Lanza E et al (2007) Elevated serum concentrations of insulin and glucose increase risk of recurrent colorectal adenomas. Gastroenterology 133(5):1423–1429

    Article  CAS  PubMed  Google Scholar 

  19. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56(4):549–580

    Article  CAS  PubMed  Google Scholar 

  20. Ibrahim YH, Yee D (2004) Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res 14(4):261–269

    Article  CAS  PubMed  Google Scholar 

  21. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579–591

    Article  CAS  PubMed  Google Scholar 

  22. Smith MR, Lee H, Nathan DM (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91(4):1305–1308

    Article  CAS  PubMed  Google Scholar 

  23. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P et al (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279(5350):563–566

    Article  CAS  PubMed  Google Scholar 

  24. Giovannucci E, Rimm EB, Liu Y, Willett WC (2004) Height, predictors of C-peptide and cancer risk in men. Int J Epidemiol 33(1):217–225

    Article  Google Scholar 

  25. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB (2000) Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 85(11):4258–4265

    Article  CAS  PubMed  Google Scholar 

  26. Kaaks R, Lukanova A, Rinaldi S, Biessy C, Söderberg S, Olsson T et al (2003) Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 12(4):309–315

    Article  CAS  PubMed  Google Scholar 

  27. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J (1990) Post-load plasma glucose and cancer mortality in middle-aged men and women. 12-year follow-up findings of the Chicago Heart Association Detection Project in Industry. Am J Epidemiol 131(2):254–262

    Article  CAS  PubMed  Google Scholar 

  28. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293(2):194–202

    Article  CAS  PubMed  Google Scholar 

  29. Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G et al (2006) Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 49(5):945–952

    Article  CAS  PubMed  Google Scholar 

  30. Duan W, Shen X, Lei J, Xu Q, Yu Y, Li R et al (2014) Hyperglycemia, a neglected factor during cancer progression. Biomed Res Int 2014:461917

    Article  PubMed  PubMed Central  Google Scholar 

  31. Berster JM, Göke B (2008) Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch Physiol Biochem 114(1):84–98

    Article  CAS  PubMed  Google Scholar 

  32. Yang YX, Hennessy S, Lewis JD (2005) Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol 3(6):587–594

    Article  PubMed  Google Scholar 

  33. Chung YW, Han DS, Park KH, Eun CS, Yoo KS, Park CK (2008) Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea. Dis Colon Rectum 51(5):593–597

    Article  PubMed  Google Scholar 

  34. Yang YX, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127(4):1044–1050

    Article  CAS  PubMed  Google Scholar 

  35. Kucharska-Newton AM, Rosamond WD, Schroeder JC, McNeill AM, Coresh J, Folsom AR (2008) HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study. Lung Cancer 61(3):292–300

    Article  PubMed  Google Scholar 

  36. Shor R, Wainstein J, Oz D, Boaz M, Matas Z, Fux A et al (2008) Low HDL levels and the risk of death, sepsis and malignancy. Clin Res Cardiol 97(4):227–233

    Article  CAS  PubMed  Google Scholar 

  37. Shor R, Wainstein J, Oz D, Boaz M, Matas Z, Fux A et al (2007) Low serum LDL cholesterol levels and the risk of fever, sepsis, and malignancy. Ann Clin Lab Sci 37(4):343–348

    CAS  PubMed  Google Scholar 

  38. Gaard M, Tretli S, Urdal P (1994) Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian women. Cancer Causes Control 5(6):501–509

    Article  CAS  PubMed  Google Scholar 

  39. Wuermli L, Joerger M, Henz S, Schmid HP, Riesen WF, Thomas G et al (2005) Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 8(4):316–320

    Article  CAS  PubMed  Google Scholar 

  40. Glazer RI, Yuan H, Xie Z, Yin Y (2008) PPARgamma and PPARdelta as modulators of neoplasia and cell fate. PPAR Res 2008:247379

    Article  PubMed  PubMed Central  Google Scholar 

  41. Sertznig P, Seifert M, Tilgen W, Reichrath J (2007) Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol 212(1):1–12

    Article  CAS  PubMed  Google Scholar 

  42. Tachibana K, Yamasaki D, Ishimoto K, Doi T (2008) The Role of PPARs in cancer. PPAR Res 2008:102737

    Article  PubMed  PubMed Central  Google Scholar 

  43. Wong JH, Ho KH, Nam S, Hsu WL, Lin CH, Chang CM et al (2017) Store-operated Ca(2+) entry facilitates the lipopolysaccharide-induced cyclooxygenase-2 expression in gastric cancer cells. Sci Rep 7(1):12813

    Article  PubMed  PubMed Central  Google Scholar 

  44. Ferrer MD, Busquets-Cortés C, Capó X, Tejada S, Tur JA, Pons A et al (2019) Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases. Curr Med Chem 26(18):3225–3241

    Article  CAS  PubMed  Google Scholar 

  45. Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K (2019) Cyclooxygenase-2 in cancer: a review. J Cell Physiol 234(5):5683–5699

    Article  CAS  PubMed  Google Scholar 

  46. Trikha P, Carson WE III (2014) Signaling pathways involved in MDSC regulation. Biochim Biophys Acta 1846(1):55–65

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Van Dross RT (2009) Metabolism of anandamide by COX-2 is necessary for endocannabinoid-induced cell death in tumorigenic keratinocytes. Mol Carcinog 48(8):724–732

    Article  PubMed  Google Scholar 

  48. Wei J, Zhang J, Wang D, Cen B, Lang JD, DuBois RN (2022) The COX-2-PGE2 pathway promotes tumor evasion in colorectal adenomas. Cancer Prev Res (Phila) 15(5):285–296

    Article  CAS  PubMed  Google Scholar 

  49. Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S et al (2018) NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172(5):1022–37.e14

    Article  PubMed  PubMed Central  Google Scholar 

  50. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270(45):26746–26749

    Article  CAS  PubMed  Google Scholar 

  51. Nguyen TMD (2020) Adiponectin: role in physiology and pathophysiology. Int J Prev Med 11:136

    Article  PubMed  PubMed Central  Google Scholar 

  52. Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C et al (2003) Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 88(10):4823–4831

    Article  CAS  PubMed  Google Scholar 

  53. Fenton JI, Birmingham JM, Hursting SD, Hord NG (2008) Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Apc Min/+ colon epithelial cells. Int J Cancer 122(11):2437–2445

    Article  CAS  PubMed  Google Scholar 

  54. Pfeiler GH, Buechler C, Neumeier M, Schäffler A, Schmitz G, Ortmann O et al (2008) Adiponectin effects on human breast cancer cells are dependent on 17-beta estradiol. Oncol Rep 19(3):787–793

    CAS  PubMed  Google Scholar 

  55. Cong L, Gasser J, Zhao J, Yang B, Li F, Zhao AZ (2007) Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2. Endocr Relat Cancer 14(3):713–720

    Article  CAS  PubMed  Google Scholar 

  56. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S et al (2006) Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol 15(7):1331–1335

    CAS  Google Scholar 

  57. Frasor J, Weaver AE, Pradhan M, Mehta K (2008) Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines. Endocrinology 149(12):6272–6279

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Brocco D, Florio R, De Lellis L, Veschi S, Grassadonia A, Tinari N et al (2020) The role of dysfunctional adipose tissue in pancreatic cancer: a molecular perspective. Cancer 12(7):1849

    Article  CAS  Google Scholar 

  60. Singh M, Benencia F (2019) Inflammatory processes in obesity: focus on endothelial dysfunction and the role of adipokines as inflammatory mediators. Int Rev Immunol 38(4):157–171

    Article  PubMed  Google Scholar 

  61. Himbert C, Delphan M, Scherer D, Bowers LW, Hursting S, Ulrich CM (2017) Signals from the adipose microenvironment and the obesity-cancer link-a systematic review. Cancer Prev Res (Phila) 10(9):494–506

    Article  CAS  PubMed  Google Scholar 

  62. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S et al (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18(8):1279–1285

    Article  CAS  PubMed  Google Scholar 

  63. Baker RG, Hayden MS, Ghosh S (2011) NF-κB, inflammation, and metabolic disease. Cell Metab 13(1):11–22

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL et al (2011) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17(2):179–188

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115(5):911–919. quiz 20

    Article  CAS  PubMed  Google Scholar 

  66. Axelsson J, Heimbürger O, Lindholm B, Stenvinkel P (2005) Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 15(1):131–136

    Article  PubMed  Google Scholar 

  67. Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo JL, Naugler W et al (2007) JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab 6(5):386–397

    Article  CAS  PubMed  Google Scholar 

  68. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM et al (2008) Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 205(10):2235–2249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J et al (2013) STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 123(4):1580–1589

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Font-Burgada J, Sun B, Karin M (2016) Obesity and cancer: the oil that feeds the flame. Cell Metab 23(1):48–62

    Article  CAS  PubMed  Google Scholar 

  71. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG et al (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140(2):197–208

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Pendyala S, Neff LM, Suárez-Fariñas M, Holt PR (2011) Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis. Am J Clin Nutr 93(2):234–242

    Article  CAS  PubMed  Google Scholar 

  73. Bai Y, Sun Q (2015) Macrophage recruitment in obese adipose tissue. Obes Rev 16(2):127–136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9(6):654–659

    Article  CAS  PubMed  Google Scholar 

  75. Kim A, Shah AS, Nakamura T (2018) Extracellular vesicles: a potential novel regulator of obesity and its associated complications. Children 5(11):152

    Article  PubMed  PubMed Central  Google Scholar 

  76. Stepanian A, Bourguignat L, Hennou S, Coupaye M, Hajage D, Salomon L et al (2013) Microparticle increase in severe obesity: not related to metabolic syndrome and unchanged after massive weight loss. Obesity 21(11):2236–2243

    Article  CAS  PubMed  Google Scholar 

  77. Ferrante SC, Nadler EP, Pillai DK, Hubal MJ, Wang Z, Wang JM et al (2015) Adipocyte-derived exosomal miRNAs: a novel mechanism for obesity-related disease. Pediatr Res 77(3):447–454

    Article  CAS  PubMed  Google Scholar 

  78. Deng ZB, Poliakov A, Hardy RW, Clements R, Liu C, Liu Y et al (2009) Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance. Diabetes 58(11):2498–2505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Bao Y, Mo J, Ruan L, Li G (2015) Increased monocytic CD14+HLADR low/- myeloid-derived suppressor cells in obesity. Mol Med Rep 11(3):2322–2328

    Article  CAS  PubMed  Google Scholar 

  80. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174

    Article  CAS  PubMed Central  Google Scholar 

  81. Bähr I, Spielmann J, Quandt D, Kielstein H (2020) Obesity-associated alterations of natural killer cells and immunosurveillance of cancer. Front Immunol 11:245

    Article  PubMed  PubMed Central  Google Scholar 

  82. James BR, Tomanek-Chalkley A, Askeland EJ, Kucaba T, Griffith TS, Norian LA (2012) Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth. J Immunol 189(3):1311–1321

    Article  CAS  PubMed  Google Scholar 

  83. Hale M, Itani F, Buchta CM, Wald G, Bing M, Norian LA (2015) Obesity triggers enhanced MDSC accumulation in murine renal tumors via elevated local production of CCL2. PLoS One 10(3):e0118784

    Article  PubMed  PubMed Central  Google Scholar 

  84. James BR, Anderson KG, Brincks EL, Kucaba TA, Norian LA, Masopust D et al (2014) CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. Cancer Immunol Immunother 63(11):1213–1227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Pacifico L, Di Renzo L, Anania C, Osborn JF, Ippoliti F, Schiavo E et al (2006) Increased T-helper interferon-gamma-secreting cells in obese children. Eur J Endocrinol 154(5):691–697

    Article  CAS  PubMed  Google Scholar 

  86. Zúñiga LA, Shen WJ, Joyce-Shaikh B, Pyatnova EA, Richards AG, Thom C et al (2010) IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol 185(11):6947–6959

    Article  PubMed  Google Scholar 

  87. Deiuliis J, Shah Z, Shah N, Needleman B, Mikami D, Narula V et al (2011) Visceral adipose inflammation in obesity is associated with critical alterations in regulatory cell numbers. PLoS One 6(1):e16376

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Basen-Engquist K, Chang M (2011) Obesity and cancer risk: recent review and evidence. Curr Oncol Rep 13(1):71–76

    Article  PubMed  PubMed Central  Google Scholar 

  89. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–1638

    Article  PubMed  Google Scholar 

  90. Dahlberg SE, Schiller JH, Bonomi PB, Sandler AB, Brahmer JR, Ramalingam SS et al (2013) Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials. J Thorac Oncol 8(9):1121–1127

    Article  PubMed  PubMed Central  Google Scholar 

  91. Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K et al (2013) Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol 31(33):4229–4234

    Article  PubMed  PubMed Central  Google Scholar 

  92. Fredslund SO, Gravholt CH, Laursen BE, Jensen AB (2019) Key metabolic parameters change significantly in early breast cancer survivors: an explorative PILOT study. J Transl Med 17(1):105

    Article  PubMed  PubMed Central  Google Scholar 

  93. Westerink NL, Nuver J, Lefrandt JD, Vrieling AH, Gietema JA, Walenkamp AM (2016) Cancer treatment induced metabolic syndrome: Improving outcome with lifestyle. Crit Rev Oncol Hematol 108:128–136

    Article  CAS  PubMed  Google Scholar 

  94. Kroenke CH, Chen WY, Rosner B, Holmes MD (2005) Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23(7):1370–1378

    Article  PubMed  Google Scholar 

  95. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK et al (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst 98(24):1767–1776

    Article  Google Scholar 

  96. Blackburn GL, Wang KA (2007) Dietary fat reduction and breast cancer outcome: results from the Women’s Intervention Nutrition Study (WINS). Am J Clin Nutr 86(3):s878–s881

    Article  PubMed  Google Scholar 

  97. Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH (1990) Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol 8(8):1327–1334

    Article  CAS  PubMed  Google Scholar 

  98. Gadéa E, Thivat E, Planchat E, Morio B, Durando X (2012) Importance of metabolic changes induced by chemotherapy on prognosis of early-stage breast cancer patients: a review of potential mechanisms. Obes Rev 13(4):368–380

    Article  PubMed  Google Scholar 

  99. Gadéa É, Thivat É, Wang-Lopez Q, Viala M, Paulon R, Planchat É et al (2013) [Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies]. Bull Cancer 100(9):865–870

    Google Scholar 

  100. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011–1015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Kulkarni SK, Kaur G (2001) Pharmacodynamics of drug-induced weight gain. Drugs Today 37(8):559–571

    Article  CAS  Google Scholar 

  102. Cleary MP, Grossmann ME (2009) Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 150(6):2537–2542

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Timilshina N, Breunis H, Alibhai SM (2012) Impact of androgen deprivation therapy on weight gain differs by age in men with nonmetastatic prostate cancer. J Urol 188(6):2183–2188

    Article  CAS  PubMed  Google Scholar 

  104. Braunstein LZ, Chen MH, Loffredo M, Kantoff PW, D’Amico AV (2014) Obesity and the odds of weight gain following androgen deprivation therapy for prostate cancer. Prostate Cancer 2014:230812

    Article  PubMed  PubMed Central  Google Scholar 

  105. Moszyńska-Zielińska M, Chałubińska-Fendler J, Gottwald L, Żytko L, Bigos E, Fijuth J (2014) Does obesity hinder radiotherapy in endometrial cancer patients? The implementation of new techniques in adjuvant radiotherapy - focus on obese patients. Prz Menopauzalny 13(2):96–100

    PubMed  Google Scholar 

  106. Cao Y, Ma J (2011) Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 4(4):486–501

    Article  CAS  PubMed  Google Scholar 

  107. Togawa K, Ma H, Sullivan-Halley J, Neuhouser ML, Imayama I, Baumgartner KB et al (2014) Risk factors for self-reported arm lymphedema among female breast cancer survivors: a prospective cohort study. Breast Cancer Res 16(4):414

    Article  PubMed  PubMed Central  Google Scholar 

  108. Thomas RJ, Holm M, Williams M, Bowman E, Bellamy P, Andreyev J et al (2013) Lifestyle factors correlate with the risk of late pelvic symptoms after prostatic radiotherapy. Clin Oncol 25(4):246–251

    Article  CAS  Google Scholar 

  109. Dandapani SV, Zhang Y, Jennelle R, Lin YG (2015) Radiation-associated toxicities in obese women with endometrial cancer: more than just BMI? Scientific World Journal 2015:483208

    Article  PubMed  PubMed Central  Google Scholar 

  110. Welsh J, Thomas J, Shah D, Allen PK, Wei X, Mitchell K et al (2011) Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 81(1):91–96

    Article  PubMed  Google Scholar 

  111. Szerlip N, Rutter C, Ram N, Yovino S, Kwok Y, Maggio W et al (2011) Factors impacting volumetric white matter changes following whole brain radiation therapy. J Neurooncol 103(1):111–119

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    Phei Er Saw & Erwei Song

  2. Nanhai Translational Innovation Center of Precision Immunology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Foshan, China

    Phei Er Saw & Erwei Song

  3. Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    Erwei Song

Authors
  1. Phei Er Saw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erwei Song
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erwei Song .

Editor information

Editors and Affiliations

  1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

    Erwei Song

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Saw, P.E., Song, E. (2023). Systemic Onco-Sphere: Host Metabolic System and Cancer. In: Song, E. (eds) Tumor Ecosystem. Springer, Singapore. https://doi.org/10.1007/978-981-99-1183-7_24

Download citation

Publish with us

Policies and ethics

Search

Navigation